P
Paul Clement
Researcher at Katholieke Universiteit Leuven
Publications - 173
Citations - 6764
Paul Clement is an academic researcher from Katholieke Universiteit Leuven. The author has contributed to research in topics: Temozolomide & Medicine. The author has an hindex of 34, co-authored 151 publications receiving 5254 citations. Previous affiliations of Paul Clement include Catholic University of Leuven & university of lille.
Papers
More filters
Journal ArticleDOI
Lomustine and Bevacizumab in Progressive Glioblastoma
Wolfgang Wick,Thierry Gorlia,Martin Bendszus,Martin J.B. Taphoorn,Felix Sahm,Inga Harting,Alba A. Brandes,Walter Taal,Julien Domont,Ahmed Idbaih,Mario Campone,Paul Clement,Roger Stupp,Michel Fabbro,Emilie Le Rhun,François Dubois,Michael Weller,Andreas von Deimling,Vassilis Golfinopoulos,Jacoline C. Bromberg,Michael Platten,Martin Klein,Martin J. van den Bent +22 more
TL;DR: Despite somewhat prolonged progression‐free survival, treatment with lomustine plus bevacizumab did not confer a survival advantage over treatment with LOMustine alone in patients with progressive glioblastoma.
Journal ArticleDOI
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
Martin J. van den Bent,Alba A. Brandes,Roy Rampling,Mathilde C.M. Kouwenhoven,Johan M. Kros,Antoine F. Carpentier,Paul Clement,Marc Frenay,Mario Campone,Jean-François Baurain,Jean-Paul Armand,Martin J.B. Taphoorn,Alicia Tosoni,Heidemarie Kletzl,Barbara Klughammer,Denis Lacombe,Thierry Gorlia +16 more
TL;DR: Erlotinib has insufficient single-agent activity in unselected GBM, and the use of enzyme-inducing anticonvulsants significantly increased erlot inib clearance, but pharmacokinetic findings were not related to outcome.
Journal ArticleDOI
Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma
Roger Stupp,Monika E. Hegi,Bart Neyns,Roland Goldbrunner,Uwe Schlegel,Paul Clement,Gerhard G. Grabenbauer,Adrian F. Ochsenbein,Matthias Simon,Pierre-Yves Dietrich,Torsten Pietsch,Christine Hicking,Joerg C. Tonn,Annie Claire Diserens,Alessia Pica,Mirjam Hermisson,Stefan R. Krueger,Martin Picard,Michael Weller +18 more
TL;DR: Compared with historical controls, the addition of concomitant and adjuvant cilengitide to standard chemoradiotherapy demonstrated promising activity in patients with glioblastoma with MGMT promoter methylation.
Journal ArticleDOI
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
Brigitta G. Baumert,Brigitta G. Baumert,Monika E. Hegi,Martin J. van den Bent,Andreas von Deimling,Thierry Gorlia,Khê Hoang-Xuan,Alba A. Brandes,Guy Kantor,Martin J.B. Taphoorn,Mohamed Ben Hassel,Christian Hartmann,Christian Hartmann,Gail Ryan,David Capper,Johan M. Kros,Sebastian Kurscheid,Sebastian Kurscheid,Wolfgang Wick,Roelien H. Enting,Michele Reni,Brian Thiessen,Frédéric Dhermain,Jacoline E C Bromberg,Loïc Feuvret,Jaap C. Reijneveld,Olivier Chinot,J.M.M. Gijtenbeek,John P. Rossiter,Nicolas Dif,Carmen Balana,Jose Bravo-Marques,Paul Clement,Christine Marosi,Tzahala Tzuk-Shina,Robert A Nordal,Jeremy Rees,Denis Lacombe,Warren P. Mason,Roger Stupp,Roger Stupp +40 more
TL;DR: There was no significant difference in outcome of the overall patient population treated with either radiotherapy alone or TMZ chemotherapy alone, and further data maturation is needed for overall survival analyses and evaluation of the full predictive impact of the molecular subtypes for individualized treatment choices.
Journal ArticleDOI
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial
Jean-Pascal Machiels,Robert I. Haddad,Jérôme Fayette,Lisa Licitra,Makoto Tahara,Jan B. Vermorken,Paul Clement,Thomas Gauler,Didier Cupissol,Juan J. Grau,Joël Guigay,F. Caponigro,Gilberto de Castro,Luciano de Souza Viana,Ulrich Keilholz,Joseph M. del Campo,X.J. Cong,E. Ehrnrooth,Ezra E.W. Cohen +18 more
TL;DR: Afatinib was associated with significant improvements in progression-free survival and had a manageable safety profile and support further investigations with irreversible ERBB family blockers in HNSCC.